派林生物(000403.SZ)公告称，公司全资子公司广东双林于近日收到国家药监局药审中心下发的关于启动静注人免疫球蛋白及人凝血因子IX药品注册核查的通知。此前，广东双林已分别获得上述两款药品的补充申请受理通知书及注册上市许可受理通知书。目前，这两款药品尚须经国家药监局审批通过后方可上市。公司将按照国家有关规定，积极推进上述研发项目注册核查及审批工作，并根据后续进展情况及时履行信息披露义务。敬请广大投资者注意投资风险。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.